Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

  • End date
    Mar 22, 2023
  • participants needed
  • sponsor
    China Medical University Hospital
Updated on 22 July 2022


Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading neurodegenerative disorders. Considering the fact that aged population is rapidly growing, it has become a critical issue to find more effective medications for these two disorders. The aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD with dementia.


Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading neurodegenerative disorders. Despite some therapeutic benefits from the medications targeting at cholinergic and dopaminergic pathways in AD and PD respectively, it remains far away from a satisfied treatment goal. DAAOI-P is a D-amino acid oxidase (DAAO) inhibitor and an agent specific to facilitate NMDA receptor subunit 1 (NR1). The investigators have demonstrated that NMDA-enhancement can help PD-D patients. The aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD with dementia. In addition to evaluating clinical treatment response, multidisciplinary examinations, including electroencephalography, transcranial magnetic stimulation, magnetic resonance imaging (MRI), and psychophysical methods to analyze the changes in perceptual sensitivity to faces, emotion expressions, and biological motion recognition will be arranged to elucidate the underlying mechanism of NMDA modulation in neurodegenerative disorder.

Condition Parkinson's Disease With Dementia
Treatment Placebo, DAAOI-P
Clinical Study IdentifierNCT04470037
SponsorChina Medical University Hospital
Last Modified on22 July 2022


Yes No Not Sure

Inclusion Criteria

PD-D will be diagnosed according to the criteria proposed by Movement Disorder Society task force statement. (Emre et al. 2007) . The following wordings are modified from the task force statement. I. Core features
Diagnosis of PD according to Queen Square Brain Bank criteria
A dementia syndrome with insidious onset and slow progression, developing within the context of established PD and diagnosed by history, clinical, and mental examination, defined as
Impairment in more than one cognitive domain
Representing a decline from premorbid level
Deficits severe enough to impair daily life, independent of the impairment ascribable to motor or autonomic symptoms
MMSE score between 10-26
II. Associated clinical features
Cognitive features: Impaired attention, executive functions, visuo-spatial functions or memory. Core functions of language are largely preserved
Behavioral features
Changes in personality and mood
Hallucination• Delusions
Excessive daytime sleepiness
III. Features which do not exclude PD-D, but make the diagnosis uncertain
Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause of dementia
Time interval between the development of motor and cognitive symptoms is uncertain
IV. Features suggesting other conditions or diseases as cause of mental impairment, which
when present make it impossible to reliably diagnose PD-D
Cognitive and behavioral symptoms appearing solely in the context of other conditions
such as
Acute confusion due to systemic illnesses or drug intoxication
Major depression
Features compatible with "Probable Vascular dementia" criteria according to
NINDS-AIREN Criteria for the diagnosis of probable and possible PD-D [Probable PD-D]
Both core features must be present. In associated clinical features, typical profile
of cognitive deficits should be present in at least 2 of the 4 core cognitive domains
The presence of at least one behavioral symptom supports the diagnosis of probable
PD-D. None of group III and IV features is present. [Possible PD-D] Both core features
must be present. In associated clinical features, the cognitive impairment is atypical
in one or more domains. The behavioral symptoms are not necessary to be present. One
or more of the group III features may be present. No group IV feature is allowed to be

Exclusion Criteria

Patients taking anticholinergics within 30 days of recruitment
Patients with uncontrollable malignancy, severe heart failure, uremia under
hemodialysis, or decompensated liver cirrhosis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note